Schrödinger Inc. logo

Schrödinger Inc.

SDGR | NASDAQ
Chart Builder DCF Calculator
$30.60
+$0.36 (+1.19%)
Sep 22, 2026, 12:48 PM ET · Market open
+1.19%

Rating

Updated: Aug 14, 2026
26.1
Fundamentals Weak
Market Sentiment Neutral
Moat None

Key Statistics

Market Data

Market Cap $2.29B
1D Range
29.74 31.59
52W Range
10.95 31.59

Valuation (TTM)

PE -40.86
PB 6.87
EV/EBITDA -42.59

Valuation (NTM)

Forward PE N/A
Forward PEG 3.52
Price Target $19
Loading financial charts...

Profile

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United...

Sector Technology
Employees 850
IPO Date Feb 4, 2020
Fiscal Year January - December

Latest News

Schrödinger: Company Creation Is Now The Real Drug Business

5 days ago · seekingalpha.com

Schrödinger: Company Creation Is Now The Real Drug Business
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

5 days ago · businesswire.com

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

6 days ago · seekingalpha.com

Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?

6 days ago · zacks.com

Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs

13 days ago · businesswire.com

Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs
Schrödinger to Present at Morgan Stanley Global Healthcare Conference

21 days ago · businesswire.com

Schrödinger to Present at Morgan Stanley Global Healthcare Conference
Schrodinger Inc (SDGR) Stock Down 4.8% -- Now Undervalued? GF Score: 73/100

1 month ago · gurufocus.com

Schrodinger Inc (SDGR) Stock Down 4.8% -- Now Undervalued? GF Score: 73/100
Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript

2 months ago · seekingalpha.com

Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript
Schrodinger Q2 Earnings Call Highlights

2 months ago · marketbeat.com

Schrodinger Q2 Earnings Call Highlights
Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates

2 months ago · zacks.com

Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates

Earnings

Next Earnings
Nov 4, 2026
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
5
Consensus
Buy
Price Target
$19
Downside
-37.91%
Buy (3)
Hold (1)
Sell (0)
Analyst Details

© 2026 bestshares.com. All rights reserved.